CoChat

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial

Open access
Hori, Hiroaki, Kunugi, Hiroshi · 2012 · The Scientific World Journal

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression. Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD). We recruited 17 patients with DSM-IV major depressive episode who have failed to respond to previous treatment with a selective serotonin reuptake inhibitor. Five patients were diagnosed as having bipolar II disorder and 12 as having unipolar MDD. Patients were monitored at an ambulatory care facility every two weeks until 12 weeks. Pramipexole was added to existing medication. Depression severity was assessed with the Hamilton Depression Rating Scale 21-item version (HDRS-21). The mean maximum dosage of pramipexole was 1.6 mg (SD 0.9). The HDRS-21 total score decreased from 19.4 (SD 3.8) at baseline to 7.2 (SD 5.4) at endpoint (P<0.000001). Twelve patients (71%) were responders based on the definition of 50% or more reduction in the HDRS-21 score. Ten patients (59%) remitted (HDRS-21 total score at endpoint<8). These results were almost unchanged when the sample was confined to patients with MDD. No serious adverse events were observed. Our findings indicate that pramipexole augmentation therapy may be effective and well tolerated in refractory depressed patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1100/2012/372474

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean scores over time on the Hamilton Depression Rating Scale (HDRS) 21-item version of the sample (n = 17), based on the intent-to-treat analysis. Error bars represent standard errors of the mean.
Figure 1 Mean scores over time on the Hamilton Depression Rating Scale (HDRS) 21-item version of the sample (n = 17), based on the intent-to-treat analysis. Error bars represent standard errors of the mean.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 1997, Journal of Clinical Psychiatry, 58, 23

Cited by

See all 67

Metadata

Authors
Hori, H., & Kunugi, H.
Affiliations
National Center of Neurology and Psychiatry (JP)
Corresponding author
Kunugi, Hiroshi
Venue
The Scientific World Journal
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-8
ISSN
1537-744X (ISSN-L)
OpenAlex
W2108580074
Cited by
62
References
22
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 2 · 2021: 19 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 6
FWCI
3.76
Type
journal article
Language
en
Open access
Locations
  • The Scientific World JOURNAL (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
Funders
  • Health and Labor Sciences Research Grants
  • Mitsubishi Pharma Research Foundation
  • CREST
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
pramipexole, dopamine agonists, treatment-resistant depression, major depressive disorder, bipolar II disorder, adjunctive therapy, augmentation therapy, dopaminergic dysfunction, remission, adverse events
MeSH terms
Pramipexole, Adult, Depression, Female, Humans, Male, Middle Aged, Dopamine Agonists, Benzothiazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.